An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease

Science Translational Medicine

Volumn 7, Issue 300, 2015, Pages

  Zhang, Sufeng ^a,b,c   Ermann, Joerg ^b,d   Succi, Marc D ^a,b,d   Zhou, Allen ^b   Hamilton, Matthew J ^b,d   Cao, Bonnie ^b   Korzenik, Joshua R ^b,d   Glickman, Jonathan N ^d,e   Vemula, Praveen K ^f   Glimcher, Laurie H ^g   Traverso, Giovanni ^a,d,h   Langer, Robert ^a,c   Karp, Jeffrey M ^a,b,d,i  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MIRACA LIFE SCIENCES   (United States)

^f Institute for Stem Cell Biology and Regenerative Medicine   (India)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBYL PALMITATE; DEXAMETHASONE; ENEMA; HYDROGEL;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; COLON MUCOSA; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG RELEASE; ENCAPSULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION TARGETING HYDROGEL; MACROPHAGE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; ULCERATIVE COLITIS; ADMINISTRATION AND DOSAGE; ANIMAL; BAGG ALBINO MOUSE; BIOPSY; COLON; DRUG DELIVERY SYSTEM; DRUG EFFECTS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; BIOPSY; COLITIS; COLON; DEXAMETHASONE; DRUG DELIVERY SYSTEMS; HUMANS; HYDROGEL; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MACROPHAGES; MICE, INBRED BALB C; TREATMENT OUTCOME;

EID: 84939440005     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaa5657     Document Type: Article

References (41)

1. E. V. Loftus Jr., Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 126, 1504-1517 (2004).
2. N. A. Molodecky, I. S. Soon, D. M. Rabi, W. A. Ghali, M. Ferris, G. Chernoff, E. I. Benchimol, R. Panaccione, S. Ghosh, H. W. Barkema, G. G. Kaplan, Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142, 46-54.e42 (2012).
3. M. L. Hoivik, B. Moum, I. C. Solberg, M. Cvancarova, O. Hoie, M. H. Vatn, T. Bernklev; IBSEN Study Group, Health-related quality of life in patients with ulcerative colitis after a 10-year disease course: Results from the IBSEN study. Inflamm. Bowel Dis. 18, 1540-1549 (2012).
4. S. Ghosh, R. Mitchell, Impact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey. J. Crohns Colitis 1, 10-20 (2007).
5. A. Kornbluth, D. B. Sachar; Practice Parameters Committee of the American College of Gastroenterology, Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am. J. Gastroenterol. 105, 501-523 (2010).
6. J. P. Ediger, J. R. Walker, L. Graff, L. Lix, I. Clara, P. Rawsthorne, L. Rogala, N. Miller, C. McPhail, K. Deering, C. N. Bernstein, Predictors of medication adherence in inflammatory bowel disease. Am. J. Gastroenterol. 102, 1417-1426 (2007).
7. B. Tirosh, N. Khatib, Y. Barenholz, A. Nissan, A. Rubinstein, Transferrin as a luminal target for negatively charged liposomes in the inflamed colonic mucosa. Mol. Pharm. 6, 1083-1091 (2009).
8. G. Canny, O. Levy, G. T. Furuta, S. Narravula-Alipati, R. B. Sisson, C. N. Serhan, S. P. Colgan, Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia. Proc. Natl. Acad. Sci. U.S.A. 99, 3902-3907 (2002).
9. H. Monajemi, J. Meenan, R. Lamping, D. O. Obradov, S. A. Radema, P. W. Trown, G. N. Tytgat, S. J. Van Deventer, Inflammatory bowel disease is associated with increased mucosal levels of bactericidal/permeability-increasing protein. Gastroenterology 110, 733-739 (1996).
10. M. Ramasundara, S. T. Leach, D. A. Lemberg, A. S. Day, Defensins and inflammation: The role of defensins in inflammatory bowel disease. J. Gastroenterol. Hepatol. 24, 202-208 (2009).
11. J. Wehkamp, K. Fellermann, K. R. Herrlinger, S. Baxmann, K. Schmidt, B. Schwind, M. Duchrow, C. Wohlschlger, A. C. Feller, E. F. Stange, Human b-defensin 2 but not b-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 14, 745-752 (2002).
12. T. T. Jubeh, Y. Barenholz, A. Rubinstein, Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes. Pharm. Res. 21, 447-453 (2004).
13. T. T. Jubeh, M. Nadler-Milbauer, Y. Barenholz, A. Rubinstein, Local treatment of experimental colitis in the rat by negatively charged liposomes of catalase, TMN and SOD. J. Drug Target. 14, 155-163 (2006).
14. E. Wiener, D. Levanon, Macrophage cultures: An extracellular esterase. Science 159, 217 (1968).
15. L. Sorokin, The impact of the extracellular matrix on inflammation. Nat. Rev. Immunol. 10, 712-723 (2010).
16. M. P. Lutolf, J. L. Lauer-Fields, H. G. Schmoekel, A. T. Metters, F. E. Weber, G. B. Fields, J. A. Hubbell, Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: Engineering cell-invasion characteristics. Proc. Natl. Acad. Sci. U.S.A. 100, 5413-5418 (2003).
17. J. Patterson, J. A. Hubbell, Enhanced proteolytic degradation of molecularly engineered PEG hydrogels in response to MMP-1 and MMP-2. Biomaterials 31, 7836-7845 (2010).
18. P. K. Vemula, E. Boilard, A. Syed, N. R. Campbell, M. Muluneh, D. A. Weitz, D. M. Lee, J. M. Karp, On-demand drug delivery from self-assembled nanofibrous gels: A new approach for treatment of proteolytic disease. J. Biomed. Mater. Res. A 97, 103-110 (2011).
19. W. S. Garrett, G. M. Lord, S. Punit, G. Lugo-Villarino, S. K. Mazmanian, S. Ito, J. N. Glickman, L. H. Glimcher, Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 131, 33-45 (2007).
20. M. E. van Meeteren, M. A. Meijssen, F. J. Zijlstra, The effect of dexamethasone treatment on murine colitis. Scand. J. Gastroenterol. 35, 517-521 (2000).
21. G. Kojouharoff, W. Hans, F. Obermeier, D. N. Mnnel, T. Andus, J. Schlmerich, V. Gross, W. Falk, Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin. Exp. Immunol. 107, 353-358 (1997).
22. H. Yuan, W. S. Ji, K. X. Wu, J. X. Jiao, L. H. Sun, Y. T. Feng, Anti-inflammatory effect of Diammonium Glycyrrhizinate in a rat model of ulcerative colitis. World J. Gastroenterol. 12, 4578-4581 (2006).
23. L. Cannarile, S. Cuzzocrea, L. Santucci, M. Agostini, E. Mazzon, E. Esposito, C. Mui, M. Coppo, R. Di Paola, C. Riccardi, Glucocorticoid-induced leucine zipper is protective in Th1-mediated models of colitis. Gastroenterology 136, 530-541 (2009).
24. J. Ermann, T. Staton, J. N. Glickman, R. de Waal Malefyt, L. H. Glimcher, Nod/Ripk2 signaling in dendritic cells activates IL-17A-secreting innate lymphoid cells and drives colitis in T-bet-/-Rag2-/- (TRUC) mice. Proc. Natl. Acad. Sci. U.S.A. 111, E2559-E2566 (2014).
25. A. Dahan, G. L. Amidon, E. M. Zimmermann, Drug targeting strategies for the treatment of inflammatory bowel disease: A mechanistic update. Expert Rev. Clin. Immunol. 6, 543-550 (2010).
26. A. Lamprecht, N. Ubrich, H. Yamamoto, U. Schfer, H. Takeuchi, P. Maincent, Y. Kawashima, C. M. Lehr, Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 299, 775-781 (2001).
27. D. S. Wilson, G. Dalmasso, L. Wang, S. V. Sitaraman, D. Merlin, N. Murthy, Orally delivered thioketal nanoparticles loaded with TNF-a-siRNA target inflammation and inhibit gene expression in the intestines. Nat. Mater. 9, 923-928 (2010).
28. H. S. Sakhalkar, M. K. Dalal, A. K. Salem, R. Ansari, J. Fu, M. F. Kiani, D. T. Kurjiaka, J. Hanes, K. M. Shakesheff, D. J. Goetz, Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo. Proc. Natl. Acad. Sci. U.S. A. 100, 15895-15900 (2003).
29. H. S. Sakhalkar, J. Hanes, J. Fu, U. Benavides, R. Malgor, C. L. Borruso, L. D. Kohn, D. T. Kurjiaka, D. J. Goetz, Enhanced adhesion of ligand-conjugated biodegradable particles to colitic venules. FASEB J. 19, 792-794 (2005).
30. Food and Drug Administration, Generally Recognized as Safe (GRAS), www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/.
31. T. Gajanayake, R. Olariu, F. M. Leclre, A. Dhayani, Z. Yang, A. K. Bongoni, Y. Banz, M. A. Constantinescu, J. M. Karp, P. K. Vemula, R. Rieben, E. Vgelin, A single localized dose of enzyme-responsive hydrogel improves long-term survival of a vascularized composite allograft. Sci. Transl. Med. 6, 249ra110 (2014).
32. C. Stahn, M. Lwenberg, D. W. Hommes, F. Buttgereit, Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol. Cell. Endocrinol. 275, 71-78 (2007).
33. S. Tsurufuji, K. Sugio, F. Takemasa, The role of glucocorticoid receptor and gene expression in the anti-inflammatory action of dexamethasone. Nature 280, 408-410 (1979).
34. E. Harel, A. Rubinstein, A. Nissan, E. Khazanov, M. Nadler Milbauer, Y. Barenholz, B. Tirosh, Enhanced transferrin receptor expression by proinflammatory cytokines in enterocytes as a means for local delivery of drugs to inflamed gut mucosa. PLOS One 6, e24202 (2011).
35. F. Li, D. Y. Hui, Modified low density lipoprotein enhances the secretion of bile salt-stimulated cholesterol esterase by human monocyte-macrophages. Species-specific difference in macrophage cholesteryl ester hydrolase. J. Biol. Chem. 272, 28666-28671 (1997).
36. X. Lu, M. D. Howard, M. Mazik, J. Eldridge, J. J. Rinehart, M. Jay, M. Leggas, Nanoparticles containing anti-inflammatory agents as chemotherapy adjuvants: Optimization and in vitro characterization. AAPS J. 10, 133-140 (2008).
37. K. Higai, A. Ichikawa, K. Matsumoto, Binding of sialyl Lewis X antigen to lectin-like receptors on NK cells induces cytotoxicity and tyrosine phosphorylation of a 17-kDa protein. Biochim. Biophys. Acta 1760, 1355-1363 (2006).
38. O. Svensson, K. Thuresson, T. Arnebrant, Interactions between chitosan-modified particles and mucin-coated surfaces. J. Colloid Interface Sci. 325, 346-350 (2008).
39. W.-S. Jang, A. T. Jensen, J. L. Lutkenhaus, Confinement effects on cross-linking within electrostatic layer-by-layer assemblies containing poly(allylamine hydrochloride) and poly(acrylic acid). Macromolecules 43, 9473-9479 (2010).
40. Y. Yan, V. Kolachala, G. Dalmasso, H. Nguyen, H. Laroui, S. V. Sitaraman, D. Merlin, Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis. PLOS One 4, e6073 (2009).
41. P. P. Bradley, D. A. Priebat, R. D. Christensen, G. Rothstein,Measurement of cutaneous inflammation: Estimation of neutrophil content with an enzyme marker. J. Invest. Dermatol. 78, 206-209 (1982).